Stephen Liu
@stephenvliu.bsky.social
Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown University Lombardi Comprehensive Cancer Center, co-Host of the IASLC Podcast
#LCSM #MedSky #OncSky #HereWeGo #Steelers #LetsGoBucs
#LCSM #MedSky #OncSky #HereWeGo #Steelers #LetsGoBucs
Pinned
Stephen Liu
@stephenvliu.bsky.social
· Sep 26
Join us in downtown Washington, DC next Saturday October 4th for the DC Lung Cancer Conference, an IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25
Register today at medstarhealth.org/dclung25
Register today at medstarhealth.org/dclung25
Join us in downtown Washington, DC next Saturday October 4th for the DC Lung Cancer Conference, an IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25
Register today at medstarhealth.org/dclung25
Register today at medstarhealth.org/dclung25
September 26, 2025 at 2:26 PM
Join us in downtown Washington, DC next Saturday October 4th for the DC Lung Cancer Conference, an IASLC endorsed, 1-day CME meeting covering updates in lung cancer, featuring 58 thoughtful & dynamic faculty members. #DCLung25
Register today at medstarhealth.org/dclung25
Register today at medstarhealth.org/dclung25
Reposted by Stephen Liu
What were the key highlights from #WCLC25 on Monday?
In this #LungCancerConsidered episode, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social discuss NADIM ADJUVANT, VATS vs lobectomy, and EA5181/LS SCLC results with leading experts.
🎧 bit.ly/WCLC25Mon
In this #LungCancerConsidered episode, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social discuss NADIM ADJUVANT, VATS vs lobectomy, and EA5181/LS SCLC results with leading experts.
🎧 bit.ly/WCLC25Mon
Live From WCLC 2025: Monday Highlights | IASLC
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference.
Dr. Tin ...
bit.ly
September 9, 2025 at 9:37 AM
What were the key highlights from #WCLC25 on Monday?
In this #LungCancerConsidered episode, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social discuss NADIM ADJUVANT, VATS vs lobectomy, and EA5181/LS SCLC results with leading experts.
🎧 bit.ly/WCLC25Mon
In this #LungCancerConsidered episode, @narjustflorezmd.bsky.social & @stephenvliu.bsky.social discuss NADIM ADJUVANT, VATS vs lobectomy, and EA5181/LS SCLC results with leading experts.
🎧 bit.ly/WCLC25Mon
Reposted by Stephen Liu
Can AI transform lung cancer care? In the newest episode of #LungCancerConsidered, @stephenvliu.bsky.social speaks with @arselaprelaj.bsky.social about how artificial intelligence is changing research, diagnostics & treatment in thoracic oncology.
🎧 bit.ly/AIandLCResea...
🎧 bit.ly/AIandLCResea...
Artificial Intelligence and Lung Cancer Research | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu sits down with Dr. Arsela Prelaj to explore what happens when cutting-edge artificial intelligen ...
bit.ly
August 6, 2025 at 5:13 PM
Can AI transform lung cancer care? In the newest episode of #LungCancerConsidered, @stephenvliu.bsky.social speaks with @arselaprelaj.bsky.social about how artificial intelligence is changing research, diagnostics & treatment in thoracic oncology.
🎧 bit.ly/AIandLCResea...
🎧 bit.ly/AIandLCResea...
Reposted by Stephen Liu
Join Discussion on Treating Rare Lung Cancer Subtypes at WCLC25 - Stephen V Liu
@stephenvliu.bsky.social @solangepeters.bsky.social @mhennink.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LungCancer #WCLC25
@stephenvliu.bsky.social @solangepeters.bsky.social @mhennink.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LungCancer #WCLC25
Stephen V Liu: Join Discussion on Treating Rare Lung Cancer Subtypes at WCLC25 - OncoDaily
Stephen V Liu: Join Discussion on Treating Rare Lung Cancer Subtypes at WCLC25 / cancer, Georgetown Lombardi Comprehensive Cancer Center, Merel Hennink,
oncodaily.com
August 24, 2025 at 12:30 AM
Join Discussion on Treating Rare Lung Cancer Subtypes at WCLC25 - Stephen V Liu
@stephenvliu.bsky.social @solangepeters.bsky.social @mhennink.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LungCancer #WCLC25
@stephenvliu.bsky.social @solangepeters.bsky.social @mhennink.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LungCancer #WCLC25
Reposted by Stephen Liu
Learn what happens at September's World Conference for #LungCancer in Barcelona – no international travel needed! Our next Together Separately livestream will focus on news from this important meeting. Join us Thurs, Sept. 25 at 3:30 PM ET: LCRF.org/together
@stephenvliu.bsky.social #WCLC25
@stephenvliu.bsky.social #WCLC25
Together Separately: WCLC recap - Lung Cancer Research Foundation
This livestream is an opportunity to connect face-to-face with others who care about lung cancer. Our guest experts will discuss developments coming out of this year’s World Conference on Lung […]
LCRF.org
August 26, 2025 at 3:02 PM
Learn what happens at September's World Conference for #LungCancer in Barcelona – no international travel needed! Our next Together Separately livestream will focus on news from this important meeting. Join us Thurs, Sept. 25 at 3:30 PM ET: LCRF.org/together
@stephenvliu.bsky.social #WCLC25
@stephenvliu.bsky.social #WCLC25
Reposted by Stephen Liu
A new ROS1+ NSCLC therapy is here.
In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care.
🎧 Tune in here: bit.ly/FDATaletrect...
#IASLC #NSCLC
In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care.
🎧 Tune in here: bit.ly/FDATaletrect...
#IASLC #NSCLC
FDA Approval: Taletrectinib and ROS1 NSCLC | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for ...
bit.ly
June 26, 2025 at 2:22 PM
A new ROS1+ NSCLC therapy is here.
In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care.
🎧 Tune in here: bit.ly/FDATaletrect...
#IASLC #NSCLC
In the latest #LungCancerConsidered, @stephenvliu.bsky.social speaks with Dr. Enriqueta Felip & Dr. Jorge Nieva about the FDA approval of taletrectinib and how it fits into lung cancer care.
🎧 Tune in here: bit.ly/FDATaletrect...
#IASLC #NSCLC
Reposted by Stephen Liu
What’s the best approach to resectable EGFR-mutant NSCLC?
In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario.
🎧 bit.ly/VTBregfrnsclc
#NSCLC #EGFR
In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario.
🎧 bit.ly/VTBregfrnsclc
#NSCLC #EGFR
Virtual Tumor Board: Resectable EGFR NSCLC | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explor ...
bit.ly
July 1, 2025 at 3:33 PM
What’s the best approach to resectable EGFR-mutant NSCLC?
In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario.
🎧 bit.ly/VTBregfrnsclc
#NSCLC #EGFR
In this #LungCancerConsidered Virtual Tumor Board, @stephenvliu.bsky.social leads a discussion with Drs. Chunxia Su & Collin Blakely exploring this complex clinical scenario.
🎧 bit.ly/VTBregfrnsclc
#NSCLC #EGFR
Reposted by Stephen Liu
What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy.
🎧 bit.ly/FDAexon20
🎧 bit.ly/FDAexon20
FDA Approval: Sunvozertinib in EGFR Exon 20 NSCLC | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses EGFR exon 20 insertions and the recently approved targeted therapy for this subset of ...
bit.ly
July 15, 2025 at 8:20 PM
What does the FDA approval of sunvozertinib mean for patients with EGFR exon 20 insertions? In this week’s #LungCancerConsidered, @stephenvliu.bsky.social talks with Dr. Mariam Alexander and Dr. James Chih-Hsin Yang about the newest EGFR-targeted therapy.
🎧 bit.ly/FDAexon20
🎧 bit.ly/FDAexon20
Reposted by Stephen Liu
Last chance! 🕐 Early bird registration for #WCLC25 ends today.
Join us in Barcelona, Sept. 6–9, for the world’s leading conference on lung cancer.
✨ Discounted rates
✨ Global networking
✨ Cutting-edge research
Register today → wclc.iaslc.org/registration/
#IASLC #LungCancer #OncologyConference
Join us in Barcelona, Sept. 6–9, for the world’s leading conference on lung cancer.
✨ Discounted rates
✨ Global networking
✨ Cutting-edge research
Register today → wclc.iaslc.org/registration/
#IASLC #LungCancer #OncologyConference
June 6, 2025 at 7:02 PM
Last chance! 🕐 Early bird registration for #WCLC25 ends today.
Join us in Barcelona, Sept. 6–9, for the world’s leading conference on lung cancer.
✨ Discounted rates
✨ Global networking
✨ Cutting-edge research
Register today → wclc.iaslc.org/registration/
#IASLC #LungCancer #OncologyConference
Join us in Barcelona, Sept. 6–9, for the world’s leading conference on lung cancer.
✨ Discounted rates
✨ Global networking
✨ Cutting-edge research
Register today → wclc.iaslc.org/registration/
#IASLC #LungCancer #OncologyConference
Reposted by Stephen Liu
Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
June 1, 2025 at 2:19 PM
Herbert Loong presenting data on Sevabertinib in ERBB2/HER2 mutated NSCLC #ASCO25
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
Cohort with no prior treatment and another with no prior HER2 targeted therapy.
Reposted by Stephen Liu
New Podcast: BTOG does … Tobacco Dependency in Lung Cancer.
Dr Emma O’Dowd talks to Professor Sanjay Agrawal.
Wherever you get your podcasts or listen online
btog.org/btog-podcasts/
#LCSM #LungCancer
Dr Emma O’Dowd talks to Professor Sanjay Agrawal.
Wherever you get your podcasts or listen online
btog.org/btog-podcasts/
#LCSM #LungCancer
May 21, 2025 at 2:00 PM
New Podcast: BTOG does … Tobacco Dependency in Lung Cancer.
Dr Emma O’Dowd talks to Professor Sanjay Agrawal.
Wherever you get your podcasts or listen online
btog.org/btog-podcasts/
#LCSM #LungCancer
Dr Emma O’Dowd talks to Professor Sanjay Agrawal.
Wherever you get your podcasts or listen online
btog.org/btog-podcasts/
#LCSM #LungCancer
Reposted by Stephen Liu
From HERTHENA-Lung02 to CheckMate 816, the latest #LungCancerConsidered episode breaks down major #ASCO25 lung cancer studies. Join @narjustflorezmd.bsky.social, @stephenvliu.bsky.social, @patrickforde.bsky.social and Dr. Charu Aggarwal for expert insights.
🎧 bit.ly/ASCO25LCC
#NSCLC #SCLC
🎧 bit.ly/ASCO25LCC
#NSCLC #SCLC
ASCO 2025 Highlights | IASLC
This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe ...
bit.ly
June 6, 2025 at 8:04 PM
From HERTHENA-Lung02 to CheckMate 816, the latest #LungCancerConsidered episode breaks down major #ASCO25 lung cancer studies. Join @narjustflorezmd.bsky.social, @stephenvliu.bsky.social, @patrickforde.bsky.social and Dr. Charu Aggarwal for expert insights.
🎧 bit.ly/ASCO25LCC
#NSCLC #SCLC
🎧 bit.ly/ASCO25LCC
#NSCLC #SCLC
Join Dr. Noemi Reguart, Dr. Nicolas Girard, and me on Wednesday, June 25 at 9:30am EST (15:30 CEST) for this free webinar, where we will discuss the lung cancer highlights from #ASCO25. Global perspectives on emerging data!
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
June 6, 2025 at 4:54 PM
Join Dr. Noemi Reguart, Dr. Nicolas Girard, and me on Wednesday, June 25 at 9:30am EST (15:30 CEST) for this free webinar, where we will discuss the lung cancer highlights from #ASCO25. Global perspectives on emerging data!
us06web.zoom.us/webinar/regi...
us06web.zoom.us/webinar/regi...
Proud to be part of the phase III IMforte team - the addition of maintenance lurbinectedin to standard maintenance atezolizumab for patients with #SCLC led to an improvement in PFS (HR 0.54) and an improvement in survival (OS HR 0.73), published in @thelancet.com.
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
IRF progression-free survival and overall survival were longer in the lurbinectedin
plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit
with a higher incidence of adv...
www.thelancet.com
June 6, 2025 at 4:51 PM
Proud to be part of the phase III IMforte team - the addition of maintenance lurbinectedin to standard maintenance atezolizumab for patients with #SCLC led to an improvement in PFS (HR 0.54) and an improvement in survival (OS HR 0.73), published in @thelancet.com.
www.thelancet.com/journals/lan...
www.thelancet.com/journals/lan...
Congratulations to the newly elected SITC At-Large Directors - Drs. Tina Cascone, Aurelien Marabelle, and Ryan Sullivan! New SITC leadership joining an accomplished board in moving immunotherapy forward with the goal of long term survival for all of our patients! @sitcancer.bsky.social
June 6, 2025 at 4:37 PM
Congratulations to the newly elected SITC At-Large Directors - Drs. Tina Cascone, Aurelien Marabelle, and Ryan Sullivan! New SITC leadership joining an accomplished board in moving immunotherapy forward with the goal of long term survival for all of our patients! @sitcancer.bsky.social
Lots of lung cancer updates at #ASCO25. Listen to the latest episode of Lung Cancer Considered, the @iaslc.bsky.social podcast, for a discussion on highlights with Drs. @narjustflorezmd.bsky.social, Charu Aggarwal, @patrickforde.bsky.social and me. #LCSM
www.iaslc.org/iaslc-news/l...
www.iaslc.org/iaslc-news/l...
ASCO 2025 Highlights | IASLC
This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe ...
www.iaslc.org
June 6, 2025 at 4:33 PM
Lots of lung cancer updates at #ASCO25. Listen to the latest episode of Lung Cancer Considered, the @iaslc.bsky.social podcast, for a discussion on highlights with Drs. @narjustflorezmd.bsky.social, Charu Aggarwal, @patrickforde.bsky.social and me. #LCSM
www.iaslc.org/iaslc-news/l...
www.iaslc.org/iaslc-news/l...
Reposted by Stephen Liu
In the latest #LungCancerConsidered episode, @stephenvliu.bsky.social moderates a discussion featuring Dr. Mara Antonoff, Dr. Shankar Siva & Dr. David Carbone. They navigate a real-world case & explore current approaches to treatment & clinical decision-making.
🎧 Listen here: bit.ly/VTBresidual
🎧 Listen here: bit.ly/VTBresidual
Virtual Tumor Board: Targeting Residual Disease | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and Dr. David Car ...
bit.ly
May 15, 2025 at 2:50 PM
In the latest #LungCancerConsidered episode, @stephenvliu.bsky.social moderates a discussion featuring Dr. Mara Antonoff, Dr. Shankar Siva & Dr. David Carbone. They navigate a real-world case & explore current approaches to treatment & clinical decision-making.
🎧 Listen here: bit.ly/VTBresidual
🎧 Listen here: bit.ly/VTBresidual
Reposted by Stephen Liu
The FDA has approved telisotuzumab vedotin for MET+ NSCLC! On this #LungCancerConsidered episode, @stephenvliu.bsky.social, Dr. Mor Moskovitz and Dr. Jonathan Goldman break down what this means for lung cancer care.
🎧 Listen now: bit.ly/FDATVandMET
#LungCancer #NSCLC
🎧 Listen now: bit.ly/FDATVandMET
#LungCancer #NSCLC
FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCL ...
bit.ly
May 27, 2025 at 8:21 PM
The FDA has approved telisotuzumab vedotin for MET+ NSCLC! On this #LungCancerConsidered episode, @stephenvliu.bsky.social, Dr. Mor Moskovitz and Dr. Jonathan Goldman break down what this means for lung cancer care.
🎧 Listen now: bit.ly/FDATVandMET
#LungCancer #NSCLC
🎧 Listen now: bit.ly/FDATVandMET
#LungCancer #NSCLC
Reposted by Stephen Liu
After years of raising awareness, Dr. Bryant Lin was diagnosed with stage IV EGFR+ lung cancer. In the new #LungCancerConsidered episode, he talks with @stephenvliu.bsky.social about patient experience, treatment, and teaching cancer care.
🎧 Listen: bit.ly/LinTMLC
🎧 Listen: bit.ly/LinTMLC
Interview with Dr. Bryant Lin: Teaching My Lung Cancer | IASLC
In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Dr. Bryant Lin, Clinical Professor of Medicine at Stanford University and co-founder ...
bit.ly
May 6, 2025 at 1:48 PM
After years of raising awareness, Dr. Bryant Lin was diagnosed with stage IV EGFR+ lung cancer. In the new #LungCancerConsidered episode, he talks with @stephenvliu.bsky.social about patient experience, treatment, and teaching cancer care.
🎧 Listen: bit.ly/LinTMLC
🎧 Listen: bit.ly/LinTMLC
Reposted by Stephen Liu
To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina!
www.sitcancer.org/membership/2...
www.sitcancer.org/membership/2...
April 26, 2025 at 3:25 PM
To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina!
www.sitcancer.org/membership/2...
www.sitcancer.org/membership/2...
To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina!
www.sitcancer.org/membership/2...
www.sitcancer.org/membership/2...
April 26, 2025 at 3:25 PM
To all SITC members - election starts May 2 and I strongly support Dr. Tina Cascone as a dynamic and visionary physician scientist and translational researcher. One of the most capable and intelligent people I know - and a caring mentor and colleague. Vote Tina!
www.sitcancer.org/membership/2...
www.sitcancer.org/membership/2...
Reposted by Stephen Liu
On the new episode of #LungCancerConsidered, we dive into how the microbiome impacts lung cancer & immunotherapy. @stephenvliu.bsky.social talks with Drs. Arielle Elkrief & Bertrand Routy about what we know and what we don’t.
🎧 Listen now: bit.ly/MI-NSCLC
#LungCancer #Immunotherapy
🎧 Listen now: bit.ly/MI-NSCLC
#LungCancer #Immunotherapy
Microbiome and Immunotherapy for NSCLC | IASLC
This episode of Lung Cancer Considered takes an in-depth look at the microbiome-- what is it, and why is it important to lung cancer clinicians and researchers? ...
bit.ly
April 1, 2025 at 4:08 PM
On the new episode of #LungCancerConsidered, we dive into how the microbiome impacts lung cancer & immunotherapy. @stephenvliu.bsky.social talks with Drs. Arielle Elkrief & Bertrand Routy about what we know and what we don’t.
🎧 Listen now: bit.ly/MI-NSCLC
#LungCancer #Immunotherapy
🎧 Listen now: bit.ly/MI-NSCLC
#LungCancer #Immunotherapy
Reposted by Stephen Liu
🎙️ Don't miss this all-new episode of #LungCancerConsidered! Host @stephenvliu.bsky.social continues our #VirtualTumorBoard series with a complex Stage III ALK+ #NSCLC case. How should clinicians approach this patient? Listen now for expert insights! 🎧 bit.ly/VTBsIIIALK
#ALKPositive #IASLC
#ALKPositive #IASLC
Virtual Tumor Board: Stage III ALK+ NSCLC | IASLC
This IASLC Virtual Tumor Board episode focuses on a patient with stage III ALK-positive NSCLC. ALK fusions are present in about 5% of NSCLC and there are now si ...
bit.ly
March 20, 2025 at 6:37 PM
🎙️ Don't miss this all-new episode of #LungCancerConsidered! Host @stephenvliu.bsky.social continues our #VirtualTumorBoard series with a complex Stage III ALK+ #NSCLC case. How should clinicians approach this patient? Listen now for expert insights! 🎧 bit.ly/VTBsIIIALK
#ALKPositive #IASLC
#ALKPositive #IASLC
Reposted by Stephen Liu
Disclosure: For someone like me, who was dx w stage 4 #lungcancer in 2022 and have been cancer-free for 2 years, a cancer vaccine is one of the most promising ways to prevent cancer from coming back. Always a pleasure to learn from @stephenvliu.bsky.social. #lcsm #oncosky wtop.com/drugs-and-me...
Amid funding concerns, promising lung cancer vaccines could be available in next few years - WTOP News
Clinical trials to develop a lung cancer vaccine to treat or prevent the most deadly form of cancer in the U.S. could be available in “the next few years.”
wtop.com
March 11, 2025 at 10:27 PM
Disclosure: For someone like me, who was dx w stage 4 #lungcancer in 2022 and have been cancer-free for 2 years, a cancer vaccine is one of the most promising ways to prevent cancer from coming back. Always a pleasure to learn from @stephenvliu.bsky.social. #lcsm #oncosky wtop.com/drugs-and-me...